CanActgx ® by Product

Available for both solid tumor and liquid biopsies, the CanActgx ® choice of reports includes

Request a Test

The CanAct® C reports and assays offer single gene cancer reports that are commonly having known or emerging associations with tumor development and behavior in different cancer types. The CanAct® C reports and assays are available for liquid and solid tumor samples.

Solid tumor & Liquid Biopsy

CanAct CKRAS

Detection of the main mutations of exon 2 (codons 12, 13), exon 3 (codons 59, 61) and exon 4 (codons 117, 146) of KRAS gene

Mainly involved in colorectal and lung cancers and also involved in pancreas, thyroid, myeloid neoplasms

Catalog Numbers:
Solid Tumor: CNACT-101
Liquid Biopsy: CNACT-201

CanAct CNRAS

Detection of the main mutations of exon 2 (codons 12, 13), exon 3 (codons 59, 61) and exon 4 (codons 117, 146) of NRAS gene

Mainly involved in colorectal cancer and also involved in AML, melanoma, lung and thyroid cancers

Catalog Numbers:
Solid Tumor: CNACT-102
Liquid Biopsy: CNACT-202

CanAct CEGFR

Detection of the main mutations of exons 18, 19, 20, 21 of EGFR gene

Mainly involved in lung cancer

Catalog Numbers:
Solid Tumor: CNACT-103
Liquid Biopsy: CNACT-203

CanAct CEGFR+

Detection of T790M and C797S mutations of EGFR gene

Mainly involved in lung cancer

Catalog Numbers:
Solid Tumor: CNACT-104.
Liquid Biopsy: CNACT-204

CanAct CBRAF

Detection of the main mutations of codon 600 of BRAF gene

Mainly involved in colorectal cancer and also involved in melanoma, lung, thyroid, brain, ovarian cancers and non-Hodgkin Lymphoma

Catalog Numbers:
Solid Tumor: CNACT-105
Liquid Biopsy: CNACT-205

CanAct CPIK

Detection of the main mutations of codons 345, 420, 542, 545, 546, 1047, 1049 of the PIK3CA gene

Mainly involved in breast, colorectal, prostate, endometrial, cervical, lung and also other cancers.

Catalog Numbers:
Solid Tumor: CNACT-112
Liquid Biopsy: CNACT-210

Solid tumor

CanAct CThr

Detection of the main mutations of exon 2 (codons 12,13) and exon 3 (codons 61) of the genes KRAS, NRAS, HRAS and the codons 600 and 601 of the BRAF gene

Mainly involved in thyroid cancer

Catalog Numbers:
CNACT-107

CanAct CThr-F

Detection of the chromosomal translocations involving RET/PTC1: CCDC6-RET; RET/PTC2: PRKAR1A-RET; RET/PTC3: NCOA4-RET and PAX8/PPARG

Mainly involved in thyroid cancer

Catalog Numbers:
CNACT-108

CanAct CRNA

Detection of the main chromosomal translocations involving ALK, ROS1, RET and the MET exon 14 skipping

Mainly involved in lung and thyroid cancers

Catalog Numbers:
CNACT-106

CanAct CMSI

Detection of 8 mononucleotide “quasi – monomorphic” markers: BAT-25, BAT-26, NR-21, NR-22, NR-24, NR-27, CAT-25 and MONO-27 for microsatellite instability in tumour samples

Tumor agnostic

Catalog Numbers:
CNACT-110

CanAct CNTRK

Detection of the main fusion variants of the NTRK1, NTRK2 and NTRK3 genes

Tumor agnostic

Catalog Numbers:
CNACT-111

CanAct CIDH

Detection of the main mutations of IDH1 gene (codons 105 and 132) and IDH2 gene (codons 140 and 172)

Mainly involved in AML and glioma and also involved in melanoma and liver cancer

Catalog Numbers:
Solid Tumor: CNACT-109
Liquid Biopsy: CNACT-209

Blood/bone marrow

CanAct CIDH

Detection of the main mutations of IDH1 gene (codons 105 and 132) and IDH2 gene (codons 140 and 172)

Mainly involved in AML and glioma and also involved in melanoma and liver cancer

Catalog Numbers:
Solid Tumor: CNACT-109
Liquid Biopsy: CNACT-209

CanAct CDPYD

Detection, by allelic discrimination, of the DPYD gene polymorphisms DPYD*2A (IVS14+1G>A, c.1905+1G>A, rs3918290), DPYD*13 (c.1679T>G, rs55886062), DPYD D949V (c.2846A>T, rs67376798), DPYD*6 (c.2194G>A, rs1801160) and DPYD IVS10 (c.1129–5923C>G, rs75017182), associated with toxicity due to treatment with Fluoropyrimidines

Tumor agnostic

Catalog Numbers:
CNACT-206

CanAct CUGT

Detection, by allelic discrimination, of the UGT1A1 gene polymorphisms UGT1A1*1 (TA)6, UGT1A1*28 (TA)7, UGT1A1*36 (TA)5 and UGT1A1*37 (TA)8, associated with toxicity due to treatment with Irinotecan

Tumor agnostic

Catalog Numbers:
CNACT-207

The CanAct® S reports and assays offer multiple gene cancer reports that are commonly having known or emerging associations specific cancers like Lung and Colon. The CanAct® S reports and assays are available for liquid and solid tumor samples.

Solid Tumor

CanAct SCLN

Detection of more than 100 variants in KRAS and NRAS (codons 12,13,59,61,117 and 146), BRAF (codons 469,594,600), EGFR (extracellular domain mutations in exon 12)and PIK3CA (codons 542,545,1047) genes, involved in Colorectal cancer

Catalog Numbers:
Solid Tumor:CNACT-302

CanAct SLNG

Detection of more than 90 variants in EGFR (exons 18,19,20,21), ERBB2 (exon 20), KRAS (codons 12,13, 61), BRAF (codons 469,594,600) and PIK3CA (codons 542,545,1047) genes, involved in Lung cancer

Catalog Numbers:
Solid Tumor:CNACT-301

Liquid Biopsy

CanAct SCLN

Detection of 80 variants in KRAS and NRAS (codons 12,13,59,61,117 and 146), BRAF (codons 469,594,600), EGFR (extracellular domain mutations in exon 12)and PIK3CA (codons 542,545,1047) genes, involved in Colorectal cancer

Catalog Numbers:
Liquid Biopsy: CNACT-402

CanAct SLNG

Detection of 80 variants in EGFR (exons 18,19,20,21), ERBB2 (exon 20), KRAS (codons 12,13, 61), BRAF (codons 469,594,600) and PIK3CA (codons 542,545,1047) genes, involved in Lung cancer

Catalog Numbers:
Liquid Biopsy:CNACT-401

Peripheral Blood

CanAct SPGX

Targets the most relevant variants in 20 principal genes implicated in drug metabolism pathways. Provides genotype information for 68, SNPs/INDELs and 5 CNV targets.

Genes analysed: ABCB1, APOE, , COMT, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, DRD2, F2, F5, GLP1R, MTHFR, OPRM1, PNPLA5, SLCO1B1, SULT4A1, VKORC1

Catalog Numbers:
CNACT-404

The CanAct® X reports and assays offer comprehensive highly multiplex gene panels that are involved in most cancers in addition the CanAct® X reports cover other cancer genetic attributes like microsatellite instability and tumor mutational burden. The CanAct® X reports and assays are available for liquid and solid tumor samples.

Solid tumor

CanAct X5.0

523 gene exome (all coding regions) DNA sequence analysis; including point and small indel mutations, amplification and deletions, MSI (Microsatellite İnstabilility) and TMB (Tumor Mutational Burden), 55 gene RNA transcript/translocation and exon skipping analysis

Catalog Numbers:
Solid Tumor:CNACT-701

Genes Covered

Liquid Biopsy

CanAct X5.0

523 gene exome (all coding regions) DNA sequence analysis; including point and small indel mutations, amplification and deletions, MSI (Microsatellite İnstabilility) and TMB (Tumor Mutational Burden), 23 gene rearrangement/translocation analysis

Catalog Numbers:
Liquid Biopsy:CNACT-702

Genes Coverd